Creso Pharma to be purchased for $122 million

Australian cannabis company Creso Pharma is to be purchased by Canadian-owned cannabis producer PharmaCielo for $122 million.

The ASX-listed company announced on Friday that it had entered into a scheme implementation agreement and advised that shareholders will receive the equivalent of 63 cents per share in PharmaCielo’s TSX Venture Exchange-listed stock, a 51.8 per cent premium.

PharmaCielo is a fully licensed producer of medicinal cannabis oil products in Colombia and plans to produce CBD and THC oil extracts later this year.

Creso Pharma co-founder and chief executive Miri Halperin Wernli said shareholders will benefit from being part of a “best in class and well-capitalised global medicinal cannabis company.”

“The combined companies will offer a unique combination of assets and professional skills across the cannabis value chain,” Wernli said.

In April Creso said it received firm commitments to raise $5.35 million via a series of secured loans, to support the sales and marketing of Creso’s human and animal health CBD-based products in Europe and Canada and to repay approximately $1 million in debt.


Comment Manually

I have read and agree to the Terms and Conditions and Privacy Policy.

Inside FMCG Jobs


FMCG Products



View details

Latest Poll

Will your business be taking part in the climate strike this Friday?

FREE NEWS BRIEFS Get breaking news delivered